Federal Circuit Affirms Ruling in Edwards Lifesciences v. Meril Heart Valve Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Edwards Lifesciences Co. v. Meril Life Sciences Pvt. Ltd. |
| Case Number | 22-1877 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from D.C. |
| Duration | June 2022 – March 2024 1 year 9 months |
| Outcome | Plaintiff Win — Infringement Affirmed |
| Patents at Issue | |
| Accused Products | Meril’s Myval aortic valve repair devices and associated delivery systems |
Case Overview
The Parties
⚖️ Plaintiff
Globally recognized leaders in structural heart disease therapies and hemodynamic monitoring, Edwards pioneered transcatheter heart valve technology and holds a formidable patent portfolio.
🛡️ Defendant
A growing Indian medical device company that developed the Myval transcatheter heart valve system, positioned to compete in international and U.S. TAVR markets.
Patents at Issue
This landmark case involved five U.S. patents spanning core TAVR device and delivery system technologies. These utility patents are registered with the U.S. Patent and Trademark Office (USPTO) and protect functional innovations critical to minimally invasive aortic valve replacement procedures.
- • US6878168B2 — Foundational TAVR device technology
- • US10292817B2 — Key delivery system components
- • US9393110B2 — Structural elements of transcatheter heart valve devices
- • US9119716B2 — Catheter-based delivery systems
- • US10053256B2 — Additional heart valve or delivery system technology
Developing a Medical Device?
Check if your heart valve device might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Court of Appeals for the Federal Circuit **affirmed** the lower court’s decision in Edwards Lifesciences Co. v. Meril Life Sciences Pvt. Ltd., Case No. 22-1877. The appeal was ultimately **dismissed**, cementing the prior ruling in Edwards’ favor across the infringement action. Specific damages amounts were not disclosed in the available case data; however, the nature of the affirmed infringement action suggests the lower court’s findings regarding liability were upheld in their entirety.
Key Legal Issues
The Federal Circuit’s affirmance involved upholding the lower court’s findings in a multi-patent infringement action covering both device and delivery system claims across five patents. Key legal battlegrounds in such disputes typically include claim construction of structural terms, literal infringement versus doctrine of equivalents analysis, and potential validity challenges. The appellate dismissal signifies that Meril’s arguments lacked the traction needed to overcome the deference owed to lower court factual findings on infringement, validating Edwards’ layered portfolio enforcement in the TAVR market.
Freedom to Operate (FTO) Analysis in Medical Devices
This case highlights critical IP risks in TAVR technology. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation in the TAVR space.
- View all related TAVR patents in this technology space
- See which companies are most active in structural heart IP
- Understand claim construction patterns for heart valve technology
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own medical device or technology.
- Input your device description or technical features
- AI identifies potentially blocking patents (e.g., Edwards’ portfolio)
- Get actionable risk assessment report for your TAVR product
High Risk Area
Transcatheter heart valve (TAVR) structural elements
5 Asserted Patents
Covering TAVR device & delivery systems
Design-Around Options
Feasibility depends on specific claim scope
✅ Key Takeaways
Federal Circuit affirmed infringement findings across a five-patent portfolio in TAVR technology, reinforcing the strength of layered patent claims.
Search related case law →The appeal dismissal confirms lower court deference standards were properly applied, highlighting the difficulty of overturning infringement findings at the appellate level.
Explore precedents →Frequently Asked Questions
Five U.S. patents were asserted: US6878168B2, US10292817B2, US9393110B2, US9119716B2, and US10053256B2 — covering transcatheter heart valve devices and delivery systems.
The Court of Appeals for the Federal Circuit affirmed the lower court’s infringement ruling and dismissed Meril’s appeal on March 25, 2024.
The affirmance strengthens Edwards’ enforcement posture and signals that multi-patent TAVR portfolios present durable barriers to market entry, likely influencing licensing negotiations and design-around strategies across the structural heart device industry.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit — Case 22-1877
- U.S. Patent and Trademark Office — Patent Full-Text Database
- PACER — Federal Court Records
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.